Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 127 results

The curious case of Wuhan’s Institute of Virology and remdesivir

China20-04-2021Thomas Moga

Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.

Got a patent, now where to validate?

EU22-03-2021Sarah Kostiuk-Smith

For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.

Second medical use: a regulatory perspective

UK08-02-2021Jackie Mulryne

Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.

Pricing, patents and the PMPRB in Canada

Canada14-12-2020Micheline Gravelle and Iris Cheung

Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Medicinal cannabis: what next for Brazil?

Brazil21-10-2019Ludmila Kawakami and Ana Paula Couto

Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.

Pharma: A Mexican tradeoff

Mexico30-09-2019Margarita Guerrero Gonzalez

While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.

Secondary patents: Moscow mewl

Russia30-09-2019Maxim Sobolev

An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.

The future of precision medicine part 6: reimbursement

International08-08-2019Daniel Lim

In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.

Shire Pharmaceuticals: A culture of excellence

Ireland, Japan21-05-2019

LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.

Showing 1 to 10 of 127 results

LSIPR